Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TYK2 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intratumoral, Intraperitoneal
01
Overview
TYK2 siRNA refers to small interfering RNA molecules designed to silence the expression of Tyrosine Kinase 2 (TYK2), a member of the Janus kinase (JAK) family. In the context of oncology research, specifically T-cell acute lymphoblastic leukemia (T-ALL), TYK2 has been identified as a critical survival factor. Silencing TYK2 via siRNA or shRNA induces apoptosis in T-ALL cells by downregulating the STAT1 pathway and subsequently affecting BCL2 expression. While TYK2 inhibitors (small molecules) are in clinical development for various autoimmune and oncologic conditions, TYK2 siRNA is primarily used as a research tool to validate the target's role in disease pathways.
- Other names
- TYK2 small interfering RNATYK-2 small interfering RNATYK 2 small interfering RNAsiRNA targeting TYK2
02
Targets
TRBP (TAR RNA-binding protein 2)AGO2 (Argonaute RISC catalytic component 2)TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on TYK2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TYK2 siRNA.